Equities research analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report earnings of $0.18 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Meridian Bioscience’s earnings, with the highest EPS estimate coming in at $0.19 and the lowest estimate coming in at $0.17. Meridian Bioscience posted earnings of $0.15 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 20%. The firm is expected to issue its next quarterly earnings results on Thursday, January 24th.
According to Zacks, analysts expect that Meridian Bioscience will report full year earnings of $0.75 per share for the current fiscal year, with EPS estimates ranging from $0.74 to $0.76. For the next year, analysts forecast that the company will post earnings of $0.79 per share, with EPS estimates ranging from $0.77 to $0.80. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, November 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.04. The business had revenue of $213.60 million for the quarter, compared to the consensus estimate of $51.11 million. Meridian Bioscience had a return on equity of 18.21% and a net margin of 11.17%. The business’s revenue was up 6.4% on a year-over-year basis. During the same quarter last year, the business posted $0.15 EPS.
Several analysts recently issued reports on the company. BidaskClub downgraded Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. ValuEngine raised Meridian Bioscience from a “hold” rating to a “buy” rating in a report on Monday, October 29th. Finally, Zacks Investment Research raised Meridian Bioscience from a “hold” rating to a “strong-buy” rating and set a $23.00 target price on the stock in a research note on Saturday, November 10th. One analyst has rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Meridian Bioscience has an average rating of “Buy” and a consensus price target of $19.50.
Shares of NASDAQ VIVO traded down $0.12 during mid-day trading on Monday, hitting $18.22. The company had a trading volume of 257,300 shares, compared to its average volume of 255,458. The company has a market cap of $777.53 million, a price-to-earnings ratio of 24.62 and a beta of 0.54. Meridian Bioscience has a 12 month low of $13.53 and a 12 month high of $19.84. The company has a current ratio of 5.73, a quick ratio of 3.89 and a debt-to-equity ratio of 0.27.
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 30th. Shareholders of record on Monday, November 19th will be paid a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a yield of 2.74%. The ex-dividend date is Friday, November 16th. Meridian Bioscience’s payout ratio is currently 67.57%.
In other Meridian Bioscience news, EVP Lawrence Baldini sold 35,101 shares of Meridian Bioscience stock in a transaction on Tuesday, November 13th. The stock was sold at an average price of $19.41, for a total transaction of $681,310.41. Following the sale, the executive vice president now owns 76,129 shares of the company’s stock, valued at approximately $1,477,663.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.70% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the business. Macquarie Group Ltd. bought a new stake in Meridian Bioscience during the 2nd quarter valued at $119,000. Captrust Financial Advisors bought a new stake in Meridian Bioscience during the 3rd quarter valued at $134,000. Piedmont Investment Advisors LLC bought a new stake in Meridian Bioscience during the 2nd quarter valued at $157,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in Meridian Bioscience during the 3rd quarter valued at $151,000. Finally, Itau Unibanco Holding S.A. bought a new stake in Meridian Bioscience during the 2nd quarter valued at $162,000. 89.32% of the stock is currently owned by hedge funds and other institutional investors.
About Meridian Bioscience
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.
Recommended Story: How is Preferred Stock Different from Common Stock?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.